KR20200047010A - Compositions comprising extract of Crataegi fructus and Lycopus lucidus for prevention or treatment of lipid-related cardiovascular diseases or obesity - Google Patents

Abstract

The present invention relates to a pharmaceutical composition and a food composition for preventing or treating lipid-related cardiovascular diseases or obesity, containing a mixture of a Crataegus pinnatifida fruit extract and a Lycopus lucidus extract. The composition containing the Crataegus pinnatifida fruit extract and the Lycopus lucidus extract can effectively prevent, treat or alleviate lipid-related cardiovascular diseases or obesity.

Description

Compositions comprising extract of Crataegi fructus and Lycopus lucidus for prevention or treatment of lipid-related cardiovascular diseases or obesity}

The present invention relates to a pharmaceutical composition and a food composition for the prevention or treatment of lipid-related cardiovascular disease or obesity, comprising a mixture of Sansa and Taxane extracts.

It is known that arteriosclerosis is caused by various endogenous and extrinsic factors such as weakening of the arterial vessels itself, damage caused by infection, and accumulation of cholesterol caused by lipoproteins. Although multiple factors that cause damage and degeneration of the arterial walls encourage the formation of atherosclerosis with each other, hypertension, hyperlipidemia and smoking among the risk factors independently cause atherosclerosis. Particularly in the case of hyperlipidemia with high cholesterol level in the blood due to excessive consumption of animal fat, phagocytes located between the lining of the arteries and the muscle layer contain more oil into the cytoplasm, thus accumulating fat in the artery walls.

On the other hand, hyperlipidemia refers to a condition in which fats such as free cholesterol, cholesterol esters, phospholipids, and triglycerides are abnormally increased in the blood. Hyperlipidemia usually does not manifest itself, but if there is a large amount of fat in the blood, it sticks to the walls of blood vessels and causes arteriosclerosis, which can lead to coronary heart disease, cerebrovascular disease, and peripheral blood vessel occlusion. In addition, excessive fat components can accumulate in the liver tissue and cause fatty liver.

Obesity is a term used to refer to a person's excessive weight, and pathologically refers to a case in which the so-called standard body weight index (BMI) established by the World Health Organization (WHO) is 30 or more. Diagnose. Obesity is a state in which fat is excessively accumulated in the body, and the number of fat cells in fat tissue increases or the size of fat cells increases, resulting in increased fat. Obesity is becoming more and more important because it causes major diseases such as hypertension, hyperlipidemia, heart disease, diabetes, arteriosclerosis, fatty liver, joint abnormalities, arthritis, sexual dysfunction, and cancer. If the body weight is increased by 20% than normal weight, the likelihood of developing diabetes increases 10 times as much as normal people. In addition, the heart and lung function may be weakened, which may shorten life. Complex factors such as hypertension, diabetes, hypercholesterolemia, and arteriosclerosis stress the heart function, leading to heart failure and sudden death.

As a method of lowering the lipid concentration in the blood, diet, exercise therapy, and drug therapy that suppress a high fat diet are recommended. However, diet or exercise therapy is difficult to strictly manage and implement, and there are many cases where its effectiveness is limited. As the lipid concentration reducing agent developed to date, drugs that lower cholesterol content such as bile acid binding resin, HMG-CoA reductase inhibitor, neomycin, and drugs that lower triglyceride content, such as fibrinic acid derivatives, nicotinic acid, and fish oil, are used as therapeutic agents. have. However, these drugs have side effects such as liver toxicity, gastrointestinal disorders and cancer.

Accordingly, the present inventors tried to find a natural product that has an effect of preventing or treating lipid-related cardiovascular disease or obesity, but has fewer side effects, and as a result, the Sansa and Taxane extracts inhibit arteriosclerosis, reduce the total cholesterol concentration in the blood, etc. The present invention was completed by confirming that it is effective in improving lipid-related cardiovascular disease and obesity.

Republic of Korea Registered Patent No. 10-0787175 Republic of Korea Registered Patent No. 10-0733984 Republic of Korea Registered Patent No. 10-1424335

One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of lipid-related cardiovascular diseases or obesity, comprising a mixture of Sansa extract and taxane extract.

Another object of the present invention is to provide a food composition for preventing or improving lipid-related cardiovascular disease or obesity, which comprises a mixture of Sansa extract and taxane extract.

In order to achieve the above object, an aspect of the present invention provides a pharmaceutical composition for the prevention or treatment of lipid-related cardiovascular disease or obesity, comprising a mixture of hawthorn extract and taxane extract.

Crataegi fructus ( Crataegi fructus ) refers to the fruit of the hawthorn, a rose family, and is known as a medicine for treating colds, coughs, and indigestion. Lycopus lucidus is a perennial plant of honeysuckle that grows in wetlands and waters. It is known as a medicinal material that helps to cure blood and blood caused by bruises, as well as various diseases and prenatal illness, injuries to ironware, and remedy.

As used herein, the term "prevention" refers to all actions that inhibit or delay the onset of lipid-related cardiovascular disease or obesity by administration of a pharmaceutical composition according to the present invention, and "treatment" refers to lipids by administration of the pharmaceutical composition. Suspicion of related cardiovascular disease or obesity and all actions that improve or beneficially alter the symptoms of the affected individual.

As used herein, the term "extract" refers to an extract obtained by extracting an acidic acid or taxane with an appropriate extraction solvent, an extract obtained by an extraction process, a dilution or concentrate of an extract, a dried product obtained by drying the extract, a control agent thereof, or It may be a purified product, but is not limited thereto. The extract of sanja and taxane according to the present invention can be prepared using general extraction methods, separation and purification methods known in the art. The extraction method may include hot water extraction, hot water extraction, cold needle extraction, reflux cooling extraction, or ultrasonic extraction, but is not limited thereto.

In the present invention, the extract may be prepared by extracting with an extraction solvent or by fractionating an extract prepared by extraction with an extraction solvent by adding a fractional solvent. The extraction solvent is not limited thereto, and water, an organic solvent, or a mixed solvent thereof may be used, and the organic solvent is an alcohol having 1 to 4 carbon atoms, a polar solvent such as ethyl acetate or acetone, hexane or dichloromethane. Non-polar solvents or mixed solvents of these can be used. In addition, preferably, water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof can be used.

According to an embodiment of the present invention, the hawthorn extract and the taxane extract may be hot water extract.

According to one embodiment of the present invention, the mixture may be a mixture of the Sansa extract and the taxane extract in a volume ratio of 1: 2 to 2: 1.

According to one embodiment of the invention, the cardiovascular disease is atherosclerosis, hypertension, myocardial infarction, stroke, hyperlipidemia, ischemic heart disease, cardiac arrhythmia, heart failure, angina pectoris, endocarditis, heart valve disorder, conduction disorder, and ischemic cerebrovascular disease It may be one or more selected from the group consisting of diseases, but is not limited thereto.

As used herein, the term "lipid-related cardiovascular disease" refers to a vascular disease of the circulatory system, a heart disease, or a cerebrovascular disease. Vascular diseases of the circulatory system refer to cases in which diseases occur in various organs of the large and small circulatory systems, including the heart, which are involved in the circulation of blood, and heart diseases are diseases related to the heart that is responsible for supplying blood to the human body. It refers to ischemic heart disease, cardiac arrhythmia, and heart failure. Ischemic heart disease typically includes angina pectoris, myocardial infarction, etc., and refers to an acute or chronic heart disorder that occurs because the blood supply to the myocardium decreases or stops as the disease of the coronary artery progresses. Other heart diseases include endocarditis, heart valve disorder, conduction disorder, cardiac arrhythmia, or heart failure. In particular, heart failure refers to a condition in which the heart cannot sufficiently rescue blood returning to the heart through the venous system. Cerebral vascular disease refers to a disease that occurs suddenly due to abnormalities in the cerebrovascular vessels, causing brain dysfunction, and the blood and part of the blood in the two are damaged depending on the type of outbreak, and bleeding and blood flow in the blood vessels become worse or blocked. It can be classified as ischemic cerebrovascular disease, but is not limited thereto.

According to one embodiment of the invention, the mixture may be to improve obesity symptoms by reducing triglycerides and total cholesterol in the blood.

In this specification, the term "obesity" refers to a condition in which body fat is excessive, and clinically means a body mass index of 25 in Korea and 30 or more according to the World Health Organization (WHO). In general, it means that the body weight is higher than the normal value, but it is diagnosed as obesity when the proportion of body fat among the components of the body is high even if the body weight does not go too much.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" of the present invention means that it exhibits a property that is not toxic to cells or humans exposed to the composition. The carrier may be used without limitation as long as it is known in the art, such as buffers, preservatives, painless agents, solubilizers, isotonic agents, stabilizers, bases, excipients, lubricants. In addition, the pharmaceutical composition of the present invention is formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions, respectively, according to a conventional method. You can. Furthermore, it can be used in the form of ointments, lotions, sprays, patch, creams, powders, suspensions, gels or external preparations for the skin. Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations include at least one excipient in the magnetized designated extract or magnetized designated, doin, gyeji, and licorice complex extract. It is prepared by mixing starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition, lubricants such as magnesium stearate and talc are used in addition to simple excipients. Liquid preparations for oral use may include various excipients, such as wetting agents, humectants, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are simple diluents commonly used for suspending agents, liquid solutions, emulsions, and syrups. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As the non-aqueous solvent and suspension, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. Macrogol, Tween 61, cacao butter, laurin, glycerogelatin, etc. may be used as a base for suppositories.

The content of the mixture of the Sansaja extract and the taxane extract contained in the pharmaceutical composition according to an embodiment of the present invention is not particularly limited, but 0.01 to 100% by weight based on the total weight of the final composition, more preferably 1 to 100 It may be included in a content of weight percent.

Meanwhile, the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount. The term "administration" of the present invention means to introduce a predetermined substance into an individual in an appropriate manner, and the route of administration of the composition can be administered through any general route as long as it can reach the target tissue. Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, rectal administration, but are not limited thereto.

The term "individual" refers to all animals, such as rats, mice, livestock, including humans, who may or may have developed lipid-related cardiovascular disease or obesity. Preferably, it can be a mammal, including a human.

The term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and does not cause side effects, and the effective dose level is the patient's sex, age, and weight Good for factors and other medical fields, including health, health condition, type of disease, severity, drug activity, sensitivity to the drug, administration method, administration time, route of administration, and rate of discharge, duration of treatment, combination or drug used concurrently It can be readily determined by those skilled in the art according to known factors. Preferably, the pharmaceutical composition comprising the magnetized designated extract of the present invention or the magnetized designated, doin, gyeji, and licorice complex extract is administered at 0.0001 to 1000 mg / kg body weight per day, preferably at 0.001 to 500 mg / kg body weight per day. can do. The administration may be the above-mentioned recommended dose once a day, or may be divided into several times.

Since the mixture of the Sansaja extract and the Taxane extract of the present invention uses natural herbal ingredients as raw materials, it can be used safely because it has less side effects than general synthetic compounds.

Another aspect of the present invention provides a food composition for preventing or improving lipid-related cardiovascular disease or obesity, comprising a mixture of hawthorn extract and taxane extract.

As used herein, the term "improvement" means any action in which the symptoms of lipid-related cardiovascular disease or obesity are improved or beneficially altered by administration of the composition.

The food composition using the mixture of the Sansa extract and the taxane extract according to the present invention includes all forms of functional food, nutritional supplement, health food and food additives. . These types can be prepared in various forms according to conventional methods known in the art.

For example, as a health food, the food composition itself of the present invention may be prepared in the form of tea, juice, and drink for drinking or granulated, encapsulated, and powdered. In addition, the food composition of the present invention can be prepared in the form of a composition by mixing with a known substance or active ingredient known to have an effect of reducing body fat, improving cholesterol, and lowering blood pressure.

In addition, functional foods include beverages (including alcoholic beverages), fruits and processed foods thereof (e.g., canned fruits, canned fruits, jams, marmalades, etc.), fish, meat, and processed foods (e.g. ham, sausage corn beef) Etc.), breads and noodles (e.g., udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), juice, various drinks, cookies, syrup, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine , Vegetable protein, retort food, frozen food, various seasonings (eg, miso, soy sauce, sauce, etc.) can be prepared by adding the food composition of the present invention.

The preferred content of the food composition according to the present invention is not limited to this, but is preferably from 0.01 to 50% by weight of the total weight of the food finally produced. In order to use the food composition of the present invention in the form of a food additive, it may be prepared and used in the form of a powder or a concentrate.

In addition, the food composition of the present invention may contain various flavoring agents, natural carbohydrates, and the like, as additional components, like a conventional beverage. The carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, synthetic sweeteners such as saccharin and aspartame can be used.

The mixture of Sansa and Taxane extracts of the present invention can effectively prevent, treat or improve lipid related cardiovascular disease or obesity.

1 is a graph showing the degree of adsorption of monocytes in vascular endothelial cells according to the treatment of a mixture (CL1, CL2, CL3) of a hot water extract of Sansaja (CE), a hot water extract of Taxan (LE), and a hot water extract of Sansaja and Taxan.
Figure 2 is a result confirming the inhibitory effect of TH1-1 monocyte adhesion of the CL1 treatment group in TNF-α-treated vascular endothelial cells.
Figure 3 is a result confirming the inhibitory effect of TH2-1 monocyte adhesion of the CL2 treatment group in TNF-α-treated vascular endothelial cells.
4 is a Western blot result confirming the protein expression level of VCAM-1 and ICAM-1 in CL1 or CL2 treated groups in TNF-α-treated vascular endothelial cells.
Figure 5 is a real-time RT-PCR analysis results confirming the gene expression level of VCAM-1, ICAM-1, MCP-1, eNOS of CL1 treatment group in TNF-α-treated vascular endothelial cells.
Figure 6 is a real-time RT-PCR analysis results confirming the gene expression level of VCAM-1, ICAM-1, MCP-1, eNOS of CL2 treatment group in TNF-α-treated vascular endothelial cells.
7 is a result confirming whether the CL1 or CL2 treated group in the NF-κB nucleus moves and decomposes IκBα in TNF-α-treated vascular endothelial cells.
8 is a result confirming the activity of ERK, JNK, p38 of CL1 or CL2 treatment group in TNF-α-treated vascular endothelial cells.
FIG. 9 is a graph showing changes in triglyceride concentration in the blood of hyperlipidemia-induced mice according to treatment of a mixture (CL1, CL2, CL3) of a hot water extract of Sansaja (CE), a hot water extract of Taxan (LE), and a hot water extract of Sansaja and Taxan.
10 is a graph showing changes in total cholesterol concentration in the blood of hyperlipidemia-inducing mice according to treatment of a mixture (CL1, CL2, CL3) of a hot water extract of Sansaja (CE), a hot water extract of Taxan (LE), and a hot water extract of Sansaja and Taxan.

Hereinafter, one or more specific examples will be described in more detail through examples. However, these examples are intended to illustrate one or more embodiments by way of example, and the scope of the present invention is not limited to these examples.

Example  1: Sansa and Taklan  Preparation of extract

In order to prepare an extract of hawthorn and taxane, hot water was extracted as follows. 300 g of mountain lion and 300 g of taxane were placed in a water bath together with 3 L of bottled water, and then immersed for 1 hour, followed by extraction by heating for 4 hours. Subsequently, each extract was filtered through a filter screen, and then concentrated using a vacuum concentrator for use in the experiment.

Example  2: Sansa and Taklan  Confirmation of anti-atherosclerotic effect of extract

Example  2-1: Effect of reducing the adsorption of monocytes in vascular endothelial cells

Immune cells, such as monocytes and T-cells, penetrate into the blood vessels by recognizing inflammation or damage to blood vessels in the body's blood vessels, adsorbing on blood vessel cells through a cell attachment substance called Selectin. As a result, the inflammatory reaction and the arteriosclerosis step is accelerated. In this experiment, it was confirmed whether the Sansaja extract, the Taxane extract, or a mixture thereof inhibits monocyte adsorption in vascular endothelial cells.

The Sansaja extract (CE), the Taxan extract (LE), the Sansaja extract and the Taxan extract prepared in Example 1 were 0.5: 1 (CL1), 1: 1 (CL2), respectively. Prepare a mixed extract at a volume ratio of 1: 0.5 (CL3), treat TNF-α on vascular endothelial cells (HUVEC), and then 10 μM fluorescent material (BCECF-AM, 2 ', 7'-Bis- ( 2-Carboxyethyl) -5- (and-6) -Carboxyfluorescein, Acetoxymethyl Ester) was reacted at 37 ° C for 40 minutes, and cultured at 37 ° C with THP-1 cells.

As a result, as shown in FIG. 1, in the control group, THP-1 cells and HUVEC were combined to increase the concentration of the fluorescent substance, but in the LE, CL1, and CL2 treatment groups, this phenomenon decreased as the concentration increased, resulting in a maximum concentration of 32. %, 49% and 26%. In addition, as a result of comparing the degree of adsorption of THP-1 cells in the CL1 or CL2 treatment group, it was confirmed that the degree of adhesion of THP-1 cells decreased as the treatment concentration increased (FIGS. 2 and 3).

Example 2-2: In vascular endothelial cells TNF -expressed by α Intercellular  Effect of suppressing the expression of adhesion substances

In this experiment, it was confirmed by Western blot analysis that the treatment of CL1 or CL2 affects the expression of the intercellular adhesion substances VCAM-1 and ICAM-1 proteins in vascular endothelial cells.

As shown in FIG. 4, in the control group treated with TNF-α on vascular endothelial cells, expression of VCAM-1 and ICAM-1 was increased, but when treated with CL1 or CL2, VCAM-1 as the concentration increased. And it was confirmed that the expression of ICAM-1 is suppressed.

Example 2-3: Intercellular  Attachment substance, chemokine ( chemokine)  Expression suppression effect and eNOS  Synergistic effect

In order to check the ability of CL1 or CL2 to regulate the adhesion between the cells at the mRNA level, it was quantified by real time RT-PCR. As a result, as shown in FIG. 5, when TNF-α was treated with vascular endothelial cells, the expression of intercellular adhesion substances, chemokines and cytokines was significantly increased, but in the group treated with CL1, VCAM-1, ICAM Expression of -1, IL-1β, and MCP-1 was suppressed as the treatment concentration of CL1 increased, and eNOS involved in the relaxation of blood vessels was confirmed to increase as the treatment concentration of CL1 increased (FIG. 5).

In addition, in the group treated with CL2, expression of VCAM-1 showed a significant inhibitory effect at 100 μg / ml, and ICAM-1 was significant in the group treated with CL2 at concentrations of 50 μg / ml and 100 μg / ml. , But did not show a significant effect on MCP-1. On the other hand, eNOS showed a significant synergistic effect at low concentrations, but did not show a large effect at high concentrations (FIG. 6).

As a result, it is determined that the mixture of the Sansa and the taklan extracts can contribute to the suppression of atherosclerosis by controlling the expression of inducers that affect atherosclerosis, i.e., intercellular adhesion substances and chemokines, especially CL1 is CL2 It was confirmed that the effect of suppressing arteriosclerosis was superior.

Example 2-4: NF - κB  p65 Nuclear  Move and I κ Bα  Phosphorylation and decomposition inhibitory effect

In order to find out by what action mechanism the inhibitory effect of CL1 and CL2, which is a mixture of Sansa and Taxane extracts, against various inducing inflammations identified in the above Examples, the activity of NF-κB, the most representative transcription factor, was confirmed.

Normally, changes in IκBα, a protein that can regulate the activity of NF-κB, were examined. When TNF-α is treated on vascular endothelial cells, IκBα is degraded after phosphorylation occurs after 5 minutes. After 30 minutes, IκBα is regenerated again, and after about an hour, it returns to its original state. Therefore, in this experiment, IκBα changes between 5 and 20 minutes were observed.

As shown in FIG. 7, phosphorylation and decomposition of IκBα was observed after 5 minutes by TNF-α treatment (control), and CL1 or CL2 inhibited the degradation of IκBα until 5 minutes after TNF-α treatment. Over time, it was confirmed that protein proteolysis of IκBα was not inhibited.

On the other hand, NF-κB p65 initially binds to IκBα and remains inactive in the cytoplasm, and upon stimulation such as TNF-α, it is freely moved into the nucleus due to decomposition of IκBα, and then is bound to the target gene It produces inflammatory factors. When TNF-α is treated with vascular endothelial cells, a large amount of NF-κB p65 begins to move into the nucleus after about 10 minutes, compared to the group not treated with TNF-α. As shown in FIG. 7, it was confirmed that CL1 or CL2 inhibits NF-κB activity by inhibiting intranuclear movement of NF-κB p65 with increasing time.

Example 2-5: MAPK activity regulation in vascular endothelial cells

As confirmed in Example 2-4, the mixture of Sansaja and Taxan extract can control the expression of various inflammatory factors, and the mechanism of action was confirmed to be involved in NF-κB. Therefore, we looked at MAPK signaling, a representative signaling factor, to find additional intracellular signaling.

As shown in FIG. 8, it was confirmed that the treatment of CL1 or CL2 inhibited concentration-dependently three kinds of MAPK (ERK, JNK, p38) phosphorylated by TNF-α, and in particular, the CL1 treatment group was treated with ERK. It was confirmed that the inhibitory effect of JNK MAPK is better. These results indicate that the mixture of the Sansa and the taxane extracts significantly regulates the signaling of NF-κB and at the same time regulates the expression of various inflammatory factors by controlling three MAPKs.

Example 3: Confirmation of antihyperlipidemic effect of Sansa and Taxane extract in mouse model

Example 3-1: Poloxamer-407 induced hyperlipidemia model

C57BL / 6J (6 weeks old, male, 18-22 g) used for this experiment was purchased from Daehan Biolink (Korea). The experimental animals were purified with a two-week stabilization period, and during the stabilization period, all the experimental groups were fed free diet (Purina, Korea). The conditions of the animal breeding room are general animal breeding systems (22 ± 2 ° C), 12 hours of the day were illuminated with 200-300 Lux, and all light was blocked for 12 hours.

The poloxamer-407 dissolved in physiological saline (1/2 dose based on 300 mg / 1 mL / kg) was subcutaneously administered to the mouse once to induce hyperlipidemia, and a mixture of Sansa and Taxane extract (0.5: 1, 1: 1, 1: 0.5, v / v) was administered orally twice a day for each concentration, and then, after 24 hours, blood was collected and triglyceride and total cholesterol levels were measured. On the other hand, in order to maximize the effect of the experiment, the hyperlipidemia-inducing concentration was set to 150 mg / 1 mL / kg (150T).

Example 3-2: Evaluation of efficacy of Sansaja and Taxane extract in hyperlipidemia-induced mouse model

Sansaja extract alone group (100 mg / kg), taxane extract alone group (100 mg / kg), mixture of Sansaza and taxane extract (100 mg / kg) by ratio (0.5: 1, 1: 1, 1: 0.5, v / v, CL1, CL2, and CL3, respectively, to prepare samples and confirm efficacy in the poloxamer-407 (150 mg / 1 mL / kg standard) animal model (n = 6). Atorvastatin (50 mg / kg) was used as a positive control.

As shown in FIG. 9, compared to the poloxamer-407 control group, the effect of reducing triglycerides in the Sansa extract alone group (CE) and the Taxan extract alone group (LE) was not significant, but the mixture of the Sansaza and Taxan extract (CL2) was statistical. It was confirmed to significantly reduce triglyceride (P * <0.05).

In addition, when compared with the Sansa alone group (CE) and the Taxan alone group (LE), the effect of reducing total cholesterol was statistically significant in the treatment group (CL1 and CL2) of the Sansa and Taxan extract (P ** <0.01). , P * <0.05) (FIG. 10).

So far, the present invention has been focused on the preferred embodiments. Those skilled in the art to which the present invention pertains will understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered in terms of explanation, not limitation. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the equivalent range should be interpreted as being included in the present invention.

Claims (6)

A pharmaceutical composition for the prevention or treatment of lipid-related cardiovascular disease or obesity, comprising a mixture of hawthorn extract and taxane extract.
The composition of claim 1, wherein the Sansaja extract and the Taxane extract are hot water extracts.
The composition of claim 1, wherein the mixture is a mixture of Sansa extract and Taxan extract in a volume ratio of 1: 2 to 2: 1.
According to claim 1, wherein the cardiovascular disease is atherosclerosis, hypertension, myocardial infarction, stroke, hyperlipidemia, ischemic heart disease, cardiac arrhythmia, heart failure, angina, endocarditis, heart valve disorder, conduction disorder, and ischemic cerebrovascular disease The composition is one or more selected from the group.
The composition of claim 1, wherein the mixture improves obesity symptoms by reducing triglycerides and total cholesterol in the blood.
A food composition for preventing or improving lipid-related cardiovascular disease or obesity, comprising a mixture of hawthorn extract and taxane extract.

Images